Involving Blood Clotting Factor (e.g., Involving Thrombin, Thromboplastin, Fibrinogen, Etc.) Patents (Class 435/13)
  • Patent number: 10383915
    Abstract: Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample. In certain embodiments, the growth factor release is not accompanied by clotting within the blood sample.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: August 20, 2019
    Assignee: GENERAL ELECTRIC COMPANY
    Inventors: Vasile Bogdan Neculaes, Andrew Soliz Torres, Antonio Caiafa, Brian Dun-Lan Lee, Allen Lawrence Garner
  • Patent number: 10337048
    Abstract: The present invention concerns diagnostic methods for coagulation testing involving determining anticoagulant activity elicited by a first anticoagulant in a sample comprising measuring a first Factor Xa activity in a body fluid test sample of said subject, measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, calculating an universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities and comparing the said parameter for the anticoagulation activity with predefined ranges of expected anticoagulation activity for at least three anticoagulants. Further provided is a computer program code assisting the method as well as a system for carrying out the said method as well as a kit.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 2, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Friedrich Ackermann, Andreas Calatzis
  • Patent number: 10315140
    Abstract: A substrate for use in a filter media including, for example, in a hydrocarbon fluid-water separation filter; methods of identifying the substrate; methods of making the substrate; methods of using the substrate; and methods of improving the roll off angle of the substrate. In some embodiments, the substrate includes a hydrophilic group-containing polymer or a hydrophilic group-containing polymer coating.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: June 11, 2019
    Assignee: DONALDSON COMPANY, INC.
    Inventors: Bradly G. Hauser, Stephen K. Sontag, Davis B. Moravec, Stuti S. Rajgarhia, Andrew J. Dallas, Vijay K. Kapoor, Aflal Rahmathullah, Charles S. Christ, Joseph M. Block
  • Patent number: 10295555
    Abstract: A signal reference value (SLocal) is set at which a blood coagulation reaction time (T) of a blood coagulation time reference sample measured on the basis of the result of comparing a signal value (amount of transmitted light, amount of scattered light, amount of fluorescence, or turbidity) pertaining to blood coagulation time that varies temporally according to the mixing and reaction of the blood coagulation time reference sample and a reagent and a signal reference value (S) corresponds to an expected value (Te) for the blood coagulation reaction time that has been set beforehand so as to correspond to the blood coagulation time reference sample. As a result, it is possible to use the blood coagulation time reference sample to determine the state of the reagent and enhance the reliability of measurement results by setting a unique signal reference value for each reagent container.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 21, 2019
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Chie Yabutani, Akihisa Makino, Shigeki Matsubara
  • Patent number: 10295552
    Abstract: Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: May 21, 2019
    Assignee: ATTOQUANT DIAGNOSTICS GMBH
    Inventors: Marko Poglitsch, Cornelia Schwager, Dunja Van Oyen, Martin Leitner
  • Patent number: 10266871
    Abstract: It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a P2Y12 receptor inhibitor, adenosine diphosphate and tissue factor to platelet rich plasma; (2) a step of adding a fluorogenic thrombin substrate and a calcium-containing solution thereto; and (3) a step of measuring fluorescence intensity.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: April 23, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiyuki Morishima, Yuko Honda
  • Patent number: 10191070
    Abstract: Disclosed are methods and systems for measuring serotonin in a sample using liquid chromatography and mass spectrometry.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 29, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Matthew Lee Francis Crawford, Yvonne Zamorano Wright, Russell Philip Grant
  • Patent number: 10188302
    Abstract: Featured is a method for assessing risk of a patient condition. Such a method includes providing criteria that relate predetermined parameters to each other, inputting observations into given criterion and relating observations of one or more acquired parameters, and converging the given criterion so as to provide an output representative of a patient condition. Such a method further includes translating the output into a visual form such as displaying the output on a display device.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: January 29, 2019
    Assignee: The University of Vermont and State Agriculture College
    Inventors: Kathleen B. Ziedins, Christopher M. Danforth, Thomas Orfeo, Stephen J. Everse, Kenneth G. Mann
  • Patent number: 10160813
    Abstract: A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibrin clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: December 25, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventor: Guy Reed
  • Patent number: 10132821
    Abstract: The present invention provides a processing station for automatically processing a biological sample, a system for automated real-time inventory control of consumables within a biological sample handling or assay instrument, a high throughput random access automated instrument for processing biological samples, an automated instrument for processing or analysis of a sample, and processes for automated mucoid detection and elimination. Methods of using the disclosed instruments, mucoid detection processes, and systems to process and/or analyze samples are also disclosed.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 20, 2018
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Rolf Silbert, David Opalsky, David Aaron Buse, Robert J. Rosati, Olev Tammer, Richard Capella, Matthias Merten
  • Patent number: 10132819
    Abstract: Disclosed is a method for measuring a clotting time, including: a mixing step of mixing a blood sample, an activator, a phospholipid, and a manganese ion-forming compound to obtain a specimen; and a measurement step of mixing the specimen obtained in the mixing step with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen, wherein the blood sample is mixed with the manganese ion-forming compound separately from the activator and the phospholipid in the mixing step.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: November 20, 2018
    Assignees: SYSMEX CORPORATION, SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
    Inventors: Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki, Masahiro Ieko
  • Patent number: 10060911
    Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterization and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.
    Type: Grant
    Filed: August 18, 2012
    Date of Patent: August 28, 2018
    Assignee: Protagen Aktiengesellschaft
    Inventors: Stefan Müllner, Peter Schulz-Knappe, Angelika Lueking, Heike Göhler, Jessica Schwermann
  • Patent number: 9989532
    Abstract: The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabig
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: June 5, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Dougald Monroe, Jen-Yea Chang
  • Patent number: 9970046
    Abstract: Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 15, 2018
    Assignees: SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN, SEKISUI MEDICAL CO., LTD.
    Inventors: Masahiro Ieko, Chizuru Morikawa, Keiko Hattori
  • Patent number: 9949473
    Abstract: A device and kit and method for controlling coagulation in a blood sample. The coagulation controlling agent is at least one of citrate, a protamine salt, its homologs and derivatives, benzamidine, or para-aminobenzamidine. Additives such as water soluble polymers and sugars are also contemplated. The device and kit comprise a container that contains an effective amount of thrombin and a coagulation controlling agent. The method combines thrombin and a coagulation controlling agent to stabilize thrombin or accelerate its activity in a blood sample.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: April 24, 2018
    Assignee: Becton, Dickinson and Company
    Inventors: Dougald Monroe, Shabazz Novarra, Randal Alan Hoke, Paul F. Holmes, Justyna Dudaronek
  • Patent number: 9938353
    Abstract: Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 10, 2018
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventors: Charles Dinarello, James D Crapo, Soohyun Kim
  • Patent number: 9835635
    Abstract: Disclosed is a method for measuring clotting time including: preparing a measurement sample by mixing a blood specimen suspected to contain a lupus anticoagulant, an activator, and a divalent-metal-ion-producing compound for facilitating formation of a phospholipid-containing complex; and measuring a clotting time after adding, to the measurement sample, an aqueous solution of a calcium salt as a coagulation initiator.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 5, 2017
    Assignees: SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN, SYSMEX CORPORATION
    Inventors: Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki, Masahiro Ieko
  • Patent number: 9828584
    Abstract: The present invention relates to the in vitro production of erythrocytes/granulocytes and to the treatment of myelodysplastic syndrome using a method for inducing hemoblast differentiation. The present invention provides a media composition comprising gelsolin as an active ingredient for inducing the differentiation of hematopoietic precursor cells into erythrocytes/granulocytes, and a pharmaceutical composition comprising gelsolin as an active ingredient for treating myelodysplastic syndrome. Since the composition of the present invention improves the efficiency of differentiation of hematopoietic precursor cells into erythrocytes/granulocytes while maintaining a low rate of occurrence of cell dysplasia and having the effect of improving the enucleation rate and cell survivability, the present invention can be effectively used for producing erythrocytes/granulocytes in vitro and for treating myelodysplastic syndrome.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: November 28, 2017
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Eun Jung Baek, Eun Mi Lee
  • Patent number: 9778254
    Abstract: A system and method wherein components of a reagent such as labeled antibodies are separated from a biologically active sensor surface by depositing the reagent on a carrier surface distinct from a sensor surface in a detection region. The present device provides a short, well-defined and controlled, pre-incubation time between the particles of interest in the sample fluid and the reagent, thereby increasing the reproducibility by providing all components in one detection region such as a detection chamber.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: October 3, 2017
    Assignees: KONINKLIJKE PHILIPS N.V., CONCATENO UK LIMITED
    Inventors: Femke Karina De Theije, Thea Van Der Wijk, Albert Hendrik Jan Immink, Eduard Gerard Marie Pelssers, Wilhelmina Maria Hardeman, Sandra Marlin, Gordon Thomas Jowett
  • Patent number: 9778272
    Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: October 3, 2017
    Assignees: Blood Center Research Foundation, The Medical College of Wisconsin, Inc.
    Inventor: Robert Montgomery
  • Patent number: 9744185
    Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: August 29, 2017
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Maya Margalit
  • Patent number: 9733262
    Abstract: A method for measuring blood coagulation, including: preparing a reaction solution including a plasma specimen, a blood coagulation activator, and at least one of amino-guanidine and an acid addition salt thereof; and measuring blood coagulation time by detecting a turbidity change in the reaction solution.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: August 15, 2017
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Chizuru Morikawa, Remi Nakamura, Mitsuaki Yamamoto
  • Patent number: 9683941
    Abstract: A presentation module is provided for presenting a fluid sample to a Laser-induced breakdown spectroscopy (LIBS) analysis. The presentation module comprises an inlet for admitting a fluid sample flow from a process flow, a measurement opening for co-operating with measurement optics, and a stabilizer surface facing towards the measurement opening. The stabilizer surface is adapted to form a stabilized sample flow along the stabilizer surface such that the depth and the outer surface of the sample flow are stabilized, and the surface fluctuation and depth variation of the stabilized sample slurry flow are reduced. As laser pulses are focused on the outer surface of the planar sample flow to transform at least a part of the sample into a state of a plasma, the accuracy and repeatability of the LIBS measurement are significantly improved due to the stabilized sample flow.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: June 20, 2017
    Assignee: OUTOTEC (FINLAND) OY
    Inventors: Arto Ollikainen, Kari Saloheimo, Christian Von Alfthan
  • Patent number: 9684004
    Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: June 20, 2017
    Assignee: ATTOQUANT DIAGNOSTICS GMBH
    Inventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner, Manfred Schuster
  • Patent number: 9651567
    Abstract: Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 16, 2017
    Assignee: CGT Enterprises, LLC
    Inventors: Bernat Galmés Sureda, Mariana Isabel Canaro Hirnyk, Vicente R. Cortina Giner
  • Patent number: 9623416
    Abstract: A cuvette module comprises a cuvette carrier and a cuvette held by the cuvette carrier. An intermediate chamber is formed in the cuvette carrier. The cuvette carrier comprises an electrically conductive plastic material. The cuvette has a different material than the cuvette carrier and the wettability of the cuvette carrier is greater than the wettability of the cuvette. A method transfers a predetermined amount of liquid from a transport container to a cuvette, employs a cuvette module. The method makes it easier to check whether the intermediate chamber still contains a sufficient amount of liquid.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 18, 2017
    Inventor: Holger Behnk
  • Patent number: 9581603
    Abstract: A method for diagnosing von Willebrand disease and novel polypeptides which bind to von Willebrand factor.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: February 28, 2017
    Assignees: NVH Medicinal, Centre Hospitalier Universitaire De Dijon
    Inventors: David Vandroux, Emmanuel De Maistre, Francois Coutard, Laure Dumont Di Leone
  • Patent number: 9488651
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 8, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Patent number: 9447402
    Abstract: The present invention provides a method for producing recombinant prothrombin. The method comprises: providing a vector DNA into which a gene encoding a tag and a gene encoding prothrombin are incorporated, wherein the tag is selected from the group consisting of MBP, SUMO, and NusA; and expressing a tag fusion type prothrombin in a lepidopteran insect or cultured cells of the lepidopteran insect.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: September 20, 2016
    Assignee: SYSMEX CORPORATION
    Inventors: Takahiko Bando, Mutsumi Sugai
  • Patent number: 9421225
    Abstract: The invention concerns a method and a system for producing a signal, in particular an electric signal, or a substance having a coagulating or anticoagulant effect. The method is characterized in that it is based on a source substance with coagulating effect, in particular, Ca++ ions, or an anticoagulant affect, in particular heparin. The method consists in: transforming the electromagnetic field derived from said source substance located in the chamber, into a signal, in particular an electric signal, using a transducer-receiver sensing the electromagnetic field; applying to a receiving substance located in the chamber, in particular water or a water-ethanol mixture or homeopathic granules, said signal derived from said transducer-receiver, using a transducer-transmitter. After said treatment, the receiving substance, initially inactive, has a coagulating or anticoagulant effect.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: August 23, 2016
    Assignee: DiGiBio
    Inventors: Jacques Benveniste, Didier Guillonnet
  • Patent number: 9404133
    Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 2, 2016
    Assignee: NOVOZYMES A/S
    Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
  • Patent number: 9395528
    Abstract: The present invention relates to a photographing control device, microscope and program that can simply confirm whether time lapse photography is being executed normally or not. A number of a display target round, time required for processing of the round, and the operation state of each device of an inverted microscope and a camera in the round, are displayed in a window 431 on a photographed result display screen 421 that displays the photographed result of the time lapse photography. The individual operation time of the each device of the inverted microscope and the camera from the start of the processing of a photographing point selected in a list box 433 to the completion of the photographing of a channel selected in a list box 434, is displayed in a window 435. When an image button is pressed, the image of a photographed sample is displayed. The present invention can be applied to software for controlling time lapse photography using a microscope, for example.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: July 19, 2016
    Assignee: NIKON CORPORATION
    Inventor: Takaaki Okamoto
  • Patent number: 9376544
    Abstract: The invention relates to a silicon dioxide dispersion that comprises a) an outer flowable phase containing 1) polymerizable monomers, oligomers and/or prepolymers that can be converted to polymers by non-radical reaction; and/or 2) polymers, and b) a disperse phase containing amorphous silicon dioxide. The inventive dispersion is characterized in that the average particle size dmax of the silicon dioxide as measured by small angle neutron scattering (SANS) is between 3 and 50 nm at a maximum half-width of the distribution curve of 1.5 dmax. Such a silicon dioxide dispersion can be easily manufactured even at higher concentrations of the disperse phase and can be used to produce polymer materials that have advantageous properties, especially advantageous mechanical properties.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: June 28, 2016
    Assignee: Evonik Hanse GmbH
    Inventors: Johannes Adam, Christof Roscher, Christian Eger, Thorsten Adebahr, Robert Wieczorreck, Manfred Pyrlik
  • Patent number: 9335336
    Abstract: The present invention provides a processing station for automatically processing a biological sample, a system for automated real-time inventory control of consumables within a biological sample handling or assay instrument, a high throughput random access automated instrument for processing biological samples, an automated instrument for processing or analysis of a sample, and processes for automated mucoid detection and elimination. Methods of using the disclosed instruments, mucoid detection processes, and systems to process and/or analyze samples are also disclosed.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 10, 2016
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Rolf Silbert, David Opalsky, David Aaron Buse, Robert J. Rosati, Olev Tammer
  • Patent number: 9329175
    Abstract: The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: May 3, 2016
    Assignee: Abbott Point of Care Inc.
    Inventors: Cary James Miller, John Lewis Emerson Campbell
  • Patent number: 9234902
    Abstract: A method of measuring the combined activity of both and only coagulation factors II and X for the purpose of monitoring anticoagulant therapy, and kits for using the method. The method involves mixing of test plasma from a human to be tested with specially prepared plasma deficient in both and only coagulation factors II and X but with normal levels of other factors (referred to herein as Fiix-deficient plasma or Fiix plasma), in order to correct for any possible deficiency in other coagulation factors than FII and FX in the test sample. By adding a coagulation reagent and calcium, the generation of thrombin or fibrin can be measured. Kits of the invention comprise a coagulation reagent, calcium and specially made plasma that is deficient in both and only factor II and factor FX.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: January 12, 2016
    Inventors: Pall Torfi Önundarson, Brynja R. Gudmundsdottir
  • Patent number: 9213035
    Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: December 15, 2015
    Assignees: Ethicon, Inc., Omrix Biopharmaceuticals Ltd.
    Inventors: Ashley De Anglis, Roberto Meidler, Anne Gorman, Liliana Bar, Israel Nur
  • Patent number: 9180142
    Abstract: Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: November 10, 2015
    Assignee: REDDRESS Ltd.
    Inventors: Alon Kushnir, Igal Kushnir
  • Patent number: 9138746
    Abstract: A test cartridge includes an input channel to receive a liquid sample to be tested. A sample chamber is coupled to the input channel to receive the sample. An air permeable membrane is coupled between the sample chamber and ambient to prevent passage of the sample past the membrane and stop movement of the sample in the sample chamber.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: September 22, 2015
    Assignee: Honeywell International Inc.
    Inventors: Pamela Wong, Lynn Seifried
  • Patent number: 9110062
    Abstract: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: August 18, 2015
    Inventor: Paul A. Gurbel
  • Patent number: 9081024
    Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: July 14, 2015
    Assignees: Societe Diagnostica-Stago, Assistance Publique-Hopitaux de Paris
    Inventors: Bibi Shah Soltan Mirshahi, Jeannette Soria
  • Patent number: 9034264
    Abstract: The present application provides apparatus and methods for determining the density of a fluid sample. In particular, it provides a sensor device which can be loaded with a fluid sample such as blood, and which further comprises at least one oscillating beam member or resonator. Exposure of the blood sample to clotting agents allows a clotting reaction to commence. The device allows the density of the sample fluid to be monitored with reference to the oscillation of the vibrating beam member, thus allowing the monitoring of the clotting of the fluid sample.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: May 19, 2015
    Assignee: Highland Biosciences Limited
    Inventor: Richard Day
  • Patent number: 9031701
    Abstract: An integrated system for determining a hemostasis and oxygen transport parameter of a blood sample, such as blood, is disclosed. The system includes a measurement system, such as an ultrasonic sensor, configured to determine data characterizing the blood sample. For example, the data could be displacement of the blood sample in response to ultrasonic pulses. An integrated aspect of the system may be a common sensor, sample portion or data for fast and efficient determination of both parameters. The parameters can also be used to correct or improve measured parameters. For example, physiological adjustments may be applied to the hemostatic parameters using a HCT measurement. Also, physical adjustments may be applied, such as through calibration using a speed or attenuation of the sound pulse through or by the blood sample. These parameters may be displayed on a GUI to guide treatment.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: May 12, 2015
    Assignee: HemoSonics LLC
    Inventors: Francesco Viola, William F. Walker
  • Patent number: 9028756
    Abstract: A specimen analyzing method and a specimen analyzing apparatus capable of measuring interference substances before analyzing a specimen. The method comprises a step for sucking the specimen stored in a specimen container (150) and sampling it in a first container (153), a step for optically measuring the specimen in the first container, a step for sampling the specimen in a second container (154) and preparing a specimen for measurement by mixing the specimen with a reagent in the second container, and a step for analyzing the specimen for measurement according to the results of the optical measurement of the specimen.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: May 12, 2015
    Assignee: Sysmex Corporation
    Inventors: Norimasa Yamamoto, Takashi Yamato, Naohiko Matsuo, Satoshi Iguchi
  • Publication number: 20150118213
    Abstract: The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 30, 2015
    Inventors: Nadav Orr, Yair Pilpel, Sivan Doron
  • Publication number: 20150118691
    Abstract: A method for the simultaneous measurement of proteolylic enzyme generation and clot strength in plasma or whole blood or any appropriate biological sample derived from blood. The measurement method encompasses the use of a detectable substrate which includes a moiety that can be released upon reaction with the targeted proteolytic enzyme, and elements for measurement of an increase in viscosity of clot strength.
    Type: Application
    Filed: June 20, 2013
    Publication date: April 30, 2015
    Inventors: Bas H. De Laat, Hendrik Coenraad Hemker, Leonie Pelkmans, Hilde Kelchtermans
  • Publication number: 20150111235
    Abstract: Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Remi NAKAMURA, Chizuru Morikawa, Hiroyuki Sunaga, Hirokazu Yago
  • Patent number: 8999243
    Abstract: A blood coagulation analysis device and method in which information relating to the coagulability of blood is evaluated based on a change generated in a permittivity measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 7, 2015
    Assignee: Sony Corporation
    Inventors: Yoshihito Hayashi, MarcAurele Brun, Shinji Omori, Yoichi Katsumoto, Kazumasa Sato
  • Publication number: 20150093770
    Abstract: The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventor: Andreas Rechner
  • Patent number: 8986625
    Abstract: A method for sampling a sulphur-containing solid product including supplying a gas flow comprising hydrogen sulphide, bringing the gas flow into contact with a solid reagent and reacting the solid reagent with the hydrogen sulphide contained in the gas flow, the reaction fixing the sulphur of the hydrogen sulphide by forming a sulphur-containing solid product which is different in color from the solid reagent, and recovering the sulphur-containing solid product. The invention also relates to a device suitable for the implementation of this method.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: March 24, 2015
    Assignee: Total S.A.
    Inventors: Daniel Dessort, Robert Le Van Loï, Nadine Loubere